| scholarly article | Q13442814 |
| P2093 | author name string | Lemley KV | |
| Bennett PH | |||
| Abdullah I | |||
| Myers BD | |||
| Nelson RG | |||
| Blouch K | |||
| Boothroyd DB | |||
| P433 | issue | 11 | |
| P921 | main subject | kidney disease | Q1054718 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 2095-2105 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus | |
| P478 | volume | 11 |
| Q45972129 | A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. |
| Q44475434 | ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy |
| Q36232508 | An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats |
| Q36774003 | An introduction to biomarkers: applications to chronic kidney disease. |
| Q88962158 | Cobalt treatment does not prevent glomerular morphological alterations in type 1 diabetic rats |
| Q37102238 | Diabetes and chronic kidney disease: lessons from the Pima Indians |
| Q35768430 | Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat |
| Q79991084 | Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice |
| Q35086477 | Glomerular endothelial cell injury and cross talk in diabetic kidney disease |
| Q34501882 | High glucose causes dysfunction of the human glomerular endothelial glycocalyx |
| Q90413453 | Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians |
| Q44387878 | Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy |
| Q35011234 | Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy |
| Q35226330 | Microalbuminuria: causes and implications |
| Q33677803 | Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition |
| Q36319830 | Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy |
| Q35063584 | Podocyte detachment in type 2 diabetic nephropathy |
| Q36661639 | Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes |
| Q37990717 | Proteinuria should be used as a surrogate in CKD. |
| Q42530764 | Reduced glomerular size selectivity in late streptozotocin-induced diabetes in rats: application of a distributed two-pore model |
| Q38148750 | Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria |
| Q37636034 | Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model. |
| Q94027488 | The authors reply |
| Q38147889 | The role of the glomerular endothelium in albumin handling |
| Q36723318 | Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes |
| Q91810091 | Understanding Inter-Individual Variability in Monoclonal Antibody Disposition |
| Q36538396 | What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? |
| Q37721287 | When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes |
| Q37319738 | Where does albuminuria come from in diabetic kidney disease? |
Search more.